GleamWall
中文EN

KPTI Karyopharm Therapeutics Inc.

Pharmaceutical Preparations · OTC · SEC CIK 1503802 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY6.8%
TTM net income YoY-81.9%
TTM EPS YoY-2.7%
Revenue 3-yr CAGR0.1%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-56.2%
Net margin-153.3%
FCF margin—
EBITDA margin-56.1%

Returns

ROE—
ROA-207.9%
ROIC (approx.)—
Asset turnover1.36x

Leverage & solvency

Liabilities / assets396.6%
Debt / equity—
Current ratio0.79x
Interest coverage-1.67x

Cash quality & payout

Operating cash flow / net income0.29x
Accruals ratio-147.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$146.07M$145.24M
R&D expense$125.62M$143.23M
SG&A expense$105.21M$115.44M
Operating income-$90.71M-$119.44M
Interest expense$45.85M$37.42M
Pretax income-$196.00M-$76.36M
Income tax$43,000$57,000
Net income-$196.04M-$76.42M
EBITDA-$90.41M-$119.10M
EPS (basic)-17.93-9.41
EPS (diluted)-17.93-14.00
Weighted avg. shares (diluted)10,9358,455
Balance sheet
Cash & equivalents$60.54M$62.81M
Short-term investments$3.20M$46.24M
Receivables$26.18M$30.77M
Inventory$4.04M$4.74M
Current assets$103.15M$156.46M
PP&E, net$104,000$400,000
Total assets$108.42M$164.42M
Current liabilities$92.06M$92.26M
Total liabilities$401.34M$350.44M
Shareholders' equity-$292.93M-$186.02M
Shares outstanding18.31M8.41M
Cash flow statement
Operating cash flow-$75.37M-$127.49M
Capital expenditure$0$142,000
Free cash flow-$75.37M-$127.63M
Investing cash flow$43.38M$95.47M
Financing cash flow$30.05M$41.65M
Depreciation & amortization$296,000$340,000
Stock-based compensation$14.05M$18.43M

Free plan shows the latest 2 periods; Pro shows all 17 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.